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Registries serve a
different purpose: at
their best, they
serve to measure
what is happening
in the real world of
patients irrespective
of whether those
patients are candi-
dates for the ran-
domized clinical
trials or not.The process of and the need for measuring things has occupied a central role inhuman history. The systems used have been infinitely variable, ranging from thesimple (e.g., the length of a finger or the width of the hand) to ultra-precise
ne microscopic dimensions, such as ångströms. Such systems have become so important
hat they merit designation by governmental agencies like the Bureau of Weights and
easures. Measurement systems are essential for both national and international com-
erce, as well as for individuals (although, in the latter case, there are potential signifi-
ant problems, as witnessed by how often the bathroom scale is unfriendly on Monday
ornings after holiday weekends).
There are several characteristics of ideal measurement systems: 1) they must be appli-
able to the object to be measured (for instance, measuring a coronary stent in kilograms
ould be inane); 2) they must be accurate and reproducible over the geographic range in
hich the measurement is performed (e.g., a gallon of milk should be the same volume
n every state or region); 3) it would be ideal for the systems to be harmonized and ac-
epted globally as reference standards, such as Greenwich Meridian Time, although such
armonization is rare; and 4) they must also be relevant, measuring something of value.
One might wonder where this discourse is heading. I like to think that if we do not
now how we are doing at something, then we should not be doing it. This is especially
rue in the healthcare field and herein enters the concept of longitudinal data reposito-
ies (i.e., registries). While randomized clinical trials are of essential value to the field by
arefully setting up studies to prospectively answer focused clinical questions (often in-
olving new devices or pharmaceutical agents) and attempting to minimize any potential
ias, they also have limitations, mainly by virtue of mandated protocols in very carefully
elected populations. Registries serve a different purpose: at their best, they serve to mea-
ure what is happening in the real world of patients irrespective of whether those pa-
ients are candidates for the randomized clinical trials or not.
As is true for measurement systems in general, medical registries need to contain the
mportant elements mentioned above to be maximally valuable. More specifically, they
eed to include relevant data captured on consecutive patients representing an unselected
opulation. Data definitions also must be identical for all participants and must be com-
lete, accurate, and adjudicated to document completeness and accuracy. The data mod-
les should be flexible so that they can efficiently and quickly respond to changes in the
eld, for example, changes in a specific device or application of that device to a different
atient population.
In addition, data should include both clinical and administrative short- and long-term
nformation and should be administered by a steering committee charged with ensuring
ptimal accurate utilization of data as well as the ability to interrogate the data. Finally,
t would be optimal for the data to be vetted, accepted, and used by regulatory agencies
ncluding the Food and Drug Administration (FDA) and the Centers for Medicare and
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portant decisions about safety, efficacy, approval, and
reimbursement.
The Society for Thoracic Surgeons and the American
College of Cardiology are working together in concert
with the Duke Clinical Research Institute to develop such
a measurement system for a longitudinal data repository
for transcatheter aortic valve replacement (TAVR). This
repository contains all of the essential elements described
in the previous text. All patients undergoing TAVR will
be enrolled with standardized forms that will track early
and longer-term follow-up, attempting to harmonize data
elements from around the world. The data will be com-
plete, adjudicated, and scientifically accurate. This registry
will be overseen by a steering committee, will play a cen-
tral role in “knowing what we are doing so that we can
do it better,” and will enhance our ability to identify ideal
patient selection criteria and provide benchmarks associ-
ated with optimal care. Importantly, both the CMS andFDA have offered to provide input into the elements col-
lected so that there is the potential for it to be used as a
post-market surveillance tool.
How do we then put this all together? As we stated in
the beginning, “the process of and the need for measuring
things has occupied a central role in human history.” No-
where in the medical field is this more important than
when new therapeutic strategies are developed. For this,
the transformational TAVR longitudinal data repository is
well matched with the transformational technology of
TAVR.
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